Fox Chase Cancer Center News

PHILADELPHIA (December 3, 2020)—Researchers at Fox Chase Cancer Center recently published new data showing that patients with head and neck cancer (HNC) recur just weeks after a complete operation at an under-appreciated rate and that this is associated with poor survival outcomes.

PHILADELPHIA (December 2, 2020)—In a recently published study, researchers at Fox Chase Cancer Center found that more elderly patients with localized head and neck cancer received multidisciplinary care compared with patients with advanced-stage disease.

PHILADELPHIA (November 30, 2020)–Researchers at Fox Chase Cancer Center have published a letter cautioning that website terms of use may limit how researchers can use online data, particularly with respect to online physician review information. Websites may require researchers to obtain permission to use online resources in research.

PHILADELPHIA (November 25, 2020)—In a recent study, researchers at Fox Chase Cancer Center used a new screening method to identify a previously unrecognized mechanism for resistance and responsiveness in Hodgkin lymphoma models being treated with brentuximab vedotin, also known by its brand name, Adcetris.

PHILADELPHIA (November 25, 2020)— Five Fox Chase Cancer Center physicians have been named as 2020 Top Docs by Main Line Today. Top Docs were selected by regional physicians from a variety of practices, and the physicians from Fox Chase who were honored cover a range of oncologic specialties.

PHILADELPHIA (November 19, 2020) – Sexually transmitted infections (STIs) have been linked to increased risk for several types of cancer, including prostate cancer. New research out of Fox Chase Cancer Center has shown that a history of STIs combined with a certain single-nucleotide polymorphism (SNP) associated with inflammation decreased risk for prostate cancer among a small group of Jamaican men.

PHILADELPHIA (November 17, 2020)—Results from a recently published study spearheaded by a Fox Chase Cancer Center researcher found that over the last 20 years, research funding provided by the American Head and Neck Society (AHNS) has generated considerable return on investment and achieved the society’s aims of furthering the trajectories of early career researchers.

PHILADELPHIA (November 17, 2020)—Patients with mantle cell lymphoma treated at Fox Chase Cancer Center will now have access to treatment with brexucabtagene autoleucel, also known as Tecartus, the first cell-based gene therapy approved by the Food and Drug Administration (FDA).